New drug approvals for 2020: Synthesis and clinical applications

被引：37
作者：
Yuan, Shuo [1 ,2 ]
Luo, Yong-Qiang [1 ,2 ]
Zuo, Jia-Hui [1 ,2 ]
Liu, Hui [1 ,2 ]
Li, Fang [1 ,2 ]
Yu, Bin [1 ,2 ]
机构：
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China
[2] Zhengzhou Univ, Key Lab Adv Drug Preparat Technol, Mil Educ, Zhengzhou 450001, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 215卷
基金：
中国国家自然科学基金;
关键词：
New drugs; Chemical synthesis; Clinical applications; FARNESYL-PROTEIN TRANSFERASE; PEPTIDE CGRP; OPEN-LABEL; PHASE-III; DISCOVERY; INHIBITORS; EFFICACY; POTENT; SELPERCATINIB; MULTICENTER;
D O I：
10.1016/j.ejmech.2021.113284
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
53 New drugs including 38 chemical entities and 15 biologics were approved by the U.S. Food and Drug Administration during 2020. Among the marketed drugs, 34 new small molecule drugs and 4 new diagnostic agents with privileged structures and novel clinical applications represent as promising leads for the development of new drugs with the similar indications and improved therapeutic efficacy. This review is mainly focused on the clinical applications and synthetic methods of 34 small-molecule drugs newly approved by the FDA in 2020. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：34
相关论文
共 50 条
  • [21] Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
    LaHood, Allison
    Rahman, Rifat
    McKenna, Lindsay
    Frick, Mike
    Mitnick, Carole D.
    PLOS ONE, 2022, 17 (07):
  • [22] Drug updates and approvals: 2019 in review
    Crump, Lauren Hartsell
    Benfield, Miranda
    Ramey, Caleb
    Arcara, Ashley
    Yang, Sebin
    Brown, Jenna
    Mospan, Geoffrey
    Mospan, Cortney
    NURSE PRACTITIONER, 2019, 44 (12) : 21 - 32
  • [23] Perspectives on 2015 Drug and Treatment Approvals
    Mohundro, Michael M.
    AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (06) : 5 - 8
  • [24] Synthesis and clinical application of new drugs approved by FDA in 2022
    Zhang, Jing-Yi
    Wang, Ya-Tao
    Sun, Lu
    Wang, Sai-Qi
    Chen, Zhe-Sheng
    MOLECULAR BIOMEDICINE, 2023, 4 (01):
  • [25] Synthesis and clinical application of new drugs approved by FDA in 2023
    Wang, Ya-Tao
    Yang, Peng-Cheng
    Zhang, Yan-Feng
    Sun, Jin-Feng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 265
  • [26] Approvals in 2022: overall survival, dose optimization, new approvals and beyond
    Telaraja, Deepti
    Gormley, Nicole
    Pazdur, Richard
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (04) : 207 - 208
  • [27] US FDA oncology drug approvals in 2014
    Wolford, Juliet E.
    Tewari, Krishnansu S.
    FUTURE ONCOLOGY, 2015, 11 (13) : 1931 - 1945
  • [28] Chlorpheniramine, an Old Drug with New Potential Clinical Applications: A Comprehensive Review of the Literature
    Rizvi, Syed A. A.
    Ferrer, Gustavo
    Khawaja, Uzzam A.
    Sanchez-Gonzalez, Marcos A.
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2024, 19 (02) : 137 - 145
  • [29] Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications
    Tamatam, Rekha
    Mohammed, Arifullah
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 272
  • [30] US DRUG AND BIOLOGIC PRODUCT APPROVALS DURING 1993
    BEARY, JF
    EATEN, CR
    COPMANN, TL
    WIERENGA, DE
    DRUG DEVELOPMENT RESEARCH, 1994, 32 (03) : 127 - 133
12345